{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:17:25Z","timestamp":1790983045264,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.7759\/cureus.113554","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:19:01Z","timestamp":1785302341000},"source":"Crossref","is-referenced-by-count":1,"title":["Proton Pump Inhibitor-Associated Restless Legs Syndrome"],"prefix":"10.7759","author":[{"given":"Susan D","family":"Leonard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert K","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2114026","article-title":"Gastroesophageal reflux disease","volume":"387","author":"Fass R","year":"2022","unstructured":"Fass R. Gastroesophageal reflux disease. N Engl J Med. 2022, 387:1207-16. 10.1056\/NEJMcp2114026","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.21360","article-title":"Gastroesophageal reflux disease: a review","volume":"324","author":"Maret-Ouda J","year":"2020","unstructured":"Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. JAMA. 2020, 324:2536-47. 10.1001\/jama.2020.21360","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz PO","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022, 117:27-56. 10.14309\/ajg.0000000000001538","journal-title":"Am J Gastroenterol"},{"key":"ref4","unstructured":"Protonix (pantoprazole sodium) delayed-release tablets prescribing information. (2026). Accessed. May 19, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020987s045lbl.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30412-1","article-title":"The effect of sleep on gastrointestinal functioning in common digestive diseases","volume":"5","author":"Orr WC","year":"2020","unstructured":"Orr WC, Fass R, Sundaram SS, et al.. The effect of sleep on gastrointestinal functioning in common digestive diseases. Lancet Gastroenterol Hepatol. 2020, 5:616-624. 10.1016\/S2468-1253(19)30412-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-021-00815-4","article-title":"Sorting out the relationship between gastroesophageal reflux disease and sleep","volume":"23","author":"Kurin M","year":"2021","unstructured":"Kurin M, Shibli F, Kitayama Y, Kim Y, Fass R. Sorting out the relationship between gastroesophageal reflux disease and sleep. Curr Gastroenterol Rep. 2021, 23:15. 10.1007\/s11894-021-00815-4","journal-title":"Curr Gastroenterol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.11.021","article-title":"A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease","volume":"7","author":"Gerson LB","year":"2009","unstructured":"Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009, 7:372-8; quiz 367. 10.1016\/j.cgh.2008.11.021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0340684","article-title":"Systematic analysis of proton pump inhibitors-related adverse reactions using the FDA adverse event reporting system database","volume":"21","author":"Wang Z","year":"2026","unstructured":"Wang Z, Jin J, Wang G, Zhou G, Jiang H. Systematic analysis of proton pump inhibitors-related adverse reactions using the FDA adverse event reporting system database. PLoS One. 2026, 21:e0340684. 10.1371\/journal.pone.0340684","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70436","article-title":"Multidimensional assessment of psychiatric adverse events related to proton pump inhibitors: a real-world, pharmacovigilance study","volume":"31","author":"Zhan ZQ","year":"2025","unstructured":"Zhan ZQ, Li JX, Zhang WG, Huang SY, Fang X. Multidimensional assessment of psychiatric adverse events related to proton pump inhibitors: a real-world, pharmacovigilance study. CNS Neurosci Ther. 2025, 31:e70436. 10.1111\/cns.70436","journal-title":"CNS Neurosci Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa220","article-title":"Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome","volume":"44","author":"Earley EJ","year":"2021","unstructured":"Earley EJ, Didriksen M, Spencer BR, et al.. Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome. Sleep. 2021, 44:10.1093\/sleep\/zsaa220","journal-title":"Sleep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.23247","article-title":"Restless legs syndrome: a review","volume":"335","author":"Winkelman JW","year":"2026","unstructured":"Winkelman JW, Wipper B. Restless legs syndrome: a review. JAMA. 2026, 335:703-14. 10.1001\/jama.2025.23247","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002542","article-title":"Restless legs syndrome associated with major diseases: a systematic review and new concept","volume":"86","author":"Trenkwalder C","year":"2016","unstructured":"Trenkwalder C, Allen R, H\u00f6gl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology. 2016, 86:1336-43. 10.1212\/WNL.0000000000002542","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007834.pub3","article-title":"Iron for the treatment of restless legs syndrome","volume":"1","author":"Trotti LM","year":"2019","unstructured":"Trotti LM, Becker LA. Iron for the treatment of restless legs syndrome. Cochrane Database Syst Rev. 2019, 1:CD007834. 10.1002\/14651858.CD007834.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5257285","article-title":"Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences","volume":"2018","author":"Ortiz-Guerrero G","year":"2018","unstructured":"Ortiz-Guerrero G, Amador-Mu\u00f1oz D, Calder\u00f3n-Ospina CA, L\u00f3pez-Fuentes D, Nava Mesa MO. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. Neural Plast. 2018, 2018:5257285. 10.1155\/2018\/5257285","journal-title":"Neural Plast"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.1c00185","article-title":"Proton pump inhibitor \u201clansoprazole\u201d inhibits locus coeruleus\u2019s neuronal activity and increases rapid eye movement sleep","volume":"12","author":"Mir FA","year":"2021","unstructured":"Mir FA, Jha SK. Proton pump inhibitor \u201clansoprazole\u201d inhibits locus coeruleus\u2019s neuronal activity and increases rapid eye movement sleep. ACS Chem Neurosci. 2021, 12:4265-74. 10.1021\/acschemneuro.1c00185","journal-title":"ACS Chem Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.593416","article-title":"Inhibition of tryptophan hydroxylases and monoamine oxidase-A by the proton pump inhibitor, omeprazole, in vitro and in vivo investigations","volume":"11","author":"Betari N","year":"2020","unstructured":"Betari N, Sahlholm K, Morat\u00f3 X, et al.. Inhibition of tryptophan hydroxylases and monoamine oxidase-A by the proton pump inhibitor, omeprazole, in vitro and in vivo investigations. Front Pharmacol. 2020, 11:593416. 10.3389\/fphar.2020.593416","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514794-proton-pump-inhibitor-associated-restless-legs-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:19:02Z","timestamp":1785302342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514794-proton-pump-inhibitor-associated-restless-legs-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.113554","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}